or Try an Advanced Search...

    Treatment Of Hemophilia Stocks List

    Symbol Grade Name % Change
    CNTA B Centessa Pharmaceuticals plc 8.66
    ALNY D Alnylam Pharmaceuticals, Inc. 0.44
    QURE D uniQure N.V. 0.18
    BIIB F Biogen Idec Inc. 1.29
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Hemophilia Acute Intermittent Porphyria Biopharmaceutical Biotechnology Clinical Development Deficiency Hemophilia A Idiopathic Pulmonary Fibrosis Lupus Spinal Muscular Atrophy Adeno Associated Virus Alipogene Tiparvovec Alnylam Pharmaceuticals Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency Alzheimer's Disease Amyloid Amyloidosis Antitrypsin Deficiency Applied Genetics

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Hemophilia stocks.

    Symbol Grade Name Weight
    PBE D PowerShares Dynamic Biotech & Genome 8.99
    MNTL D Tema Neuroscience and Mental Health ETF 8.09
    BIS B ProShares UltraShort Nasdaq Biotechnology 8.07
    MEDX F Horizon Kinetics Medical ETF 7.53
    BBH D Market Vectors Biotech ETF 7.44
    View all Treatment Of Hemophilia ETFs...
    Compare ETFs
    Compare MEDX to BBH Compare PBE to BBH Compare PBE to MEDX

        Treatment Of Hemophilia Stocks Recent News

        Date Stock Title
        Nov 21 QURE uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
        Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
        Nov 20 BIIB Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 BIIB Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
        Nov 19 BIIB Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
        Nov 18 BIIB Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
        Nov 18 ALNY Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
        Nov 18 BIIB Needham downgrades Biogen on slow growth of Alzheimer's drug
        Nov 18 BIIB Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
        Nov 18 ALNY ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
        Nov 18 ALNY Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
        Nov 18 BIIB Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
        Nov 18 BIIB Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
        Nov 17 ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
        Nov 15 BIIB Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Hemophilia Acute Intermittent Porphyria Biopharmaceutical Biotechnology Clinical Development Deficiency Hemophilia A Idiopathic Pulmonary Fibrosis Lupus Spinal Muscular Atrophy Adeno Associated Virus Alipogene Tiparvovec Alnylam Pharmaceuticals Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency Alzheimer's Disease Amyloid Amyloidosis Antitrypsin Deficiency Applied Genetics
        Treatment Of Hemophilia

        Treatment of hemophilia typically involves the use of replacement therapy, which involves infusions of clotting factor concentrates. These concentrates are made from donated human plasma and are designed to replace the missing clotting factor in the blood. Other treatments may include physical therapy, medications to reduce pain and swelling, and surgery to repair damaged joints.

        Browse All Tags